메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
You-Jeong Ki (Seoul National University Hospital) Bong Ki Lee (Kangwon National University) Kyung Woo Park (Seoul National University Hospital) Jang-Whan Bae (Chungbuk National University Hospital) Doyeon Hwang (Seoul National University Hospital) Jeehoon Kang (Seoul National University Hospital) Jung-Kyu Han (Seoul National University Hospital) Han-Mo Yang (Seoul National University Hospital) Hyun-Jae Kang (Seoul National University Hospital) Bon-Kwon Koo (Seoul National University Hospital) Dong-Bin Kim (Bucheon St. Mary’s Hospital) In-Ho Chae (Seoul National University Bundang Hospital) Keon-Woong Moon (St. Vincent's Hospital) Hyun Woong Park (Gyeongsang National University Hospital) Ki-Bum Won (Ulsan University Hospital) Dong Woon Jeon (National Health Insurance Service Ilsan Hospital) Kyoo-Rok Han (Kangdong Sacred Heart Hospital) Si Wan Choi (Chungnam National University Hospital) Jae Kean Ryu (Daegu Catholic University Medical Center) Myung Ho Jeong (Chonnam National University Hospital) Kwang Soo Cha (Pusan National University Hospital) Hyo-Soo Kim (Seoul National University Hospital)
저널정보
대한심장학회 Korean Circulation Journal Korean Circulation Journal Vol.52 No.4
발행연도
2022.4
수록면
304 - 319 (16page)
DOI
https://doi.org/10.4070/kcj.2021.0293

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background and Objectives: De-escalation of dual-antiplatelet therapy through dose reduction of prasugrel improved net adverse clinical events (NACEs) after acute coronary syndrome (ACS), mainly through the reduction of bleeding without an increase in ischemic outcomes. Whether the benefits of de-escalation are sustained in highly thrombotic conditions such as ST-elevation myocardial infarction (STEMI) is unknown. We aimed to assess the efficacy and safety of de-escalation therapy in patients with STEMI or non-ST-segment elevation ACS (NSTE-ACS). Methods: This is a pre-specified subgroup analysis of the HOST-REDUCE-POLYTECH-ACS trial. ACS patients were randomized to prasugrel de-escalation (5 mg daily) or conventional dose (10 mg daily) at 1-month post-percutaneous coronary intervention. The primary endpoint was a NACE, defined as a composite of all-cause death, non-fatal myocardial infarction, stent thrombosis, clinically driven revascularization, stroke, and bleeding events of grade ≥2 Bleeding Academic Research Consortium (BARC) criteria at 1 year. Results: Among 2,338 patients included in the randomization, 326 patients were diagnosed with STEMI. In patients with NSTE-ACS, the risk of the primary endpoint was significantly reduced with de-escalation (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48?0.89; p=0.006 for de-escalation vs. conventional), mainly driven by a reduced bleeding. However, in those with STEMI, there was no difference in the occurrence of the primary outcome (HR, 1.04; 95% CI, 0.48?2.26; p=0.915; p for interaction=0.271). Conclusions: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0